Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AROA BIOSURGERY LIMITED Investor Presentation 2021

Mar 16, 2021

64426_rns_2021-03-16_ff8daa7f-439c-4ad4-803e-007268dd1489.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

ASX ANNOUNCEMENT/MEDIA RELEASE 17 MARCH 2021

==> picture [53 x 53] intentionally omitted <==

AROA TO PRESENT AT NWR VIRTUAL INVESTOR CONFERENCE

==> picture [45 x 10] intentionally omitted <==

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) is pleased to announce it will present at the NWR Virtual Investor Conference on Thursday 18 March 2021.

The Company invites shareholders and investors to see Aroa Biosurgery CEO Brian Ward present an update at 8:30am AEDT on 18 March 2021.

Event: NWR Communications Virtual Investor Conference Presenting: Brian Ward (CEO, Aroa Biosurgery) Time: Thursday 18 March 2021, 8:30am AEDT for 30 minutes

Investors are invited to submit questions prior to the event to: [email protected]

Investors can register online to view the presentation here: https://us02web.zoom.us/webinar/register/WN_tbiMPa5UR4e5mD89fPd17w

For more information on the conference click here: https://nwrconference.webflow.io/

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to ‘unlocking regenerative healing for everybody’, its products are developed from the Company’s proprietary Aroa ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Clinically proven with peer reviewed publications, Aroa’s products have been used in more than four million procedures to date, with distribution into its key market of the United States by Appulse and Tela Bio. Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com/

Contacts

Investor

Simon Hinsley Investor Relations [email protected] + 61 401 809 653

Media

Australia New Zealand Matthew Wright Piet De Jong [email protected] [email protected] +61 451 896 420 +64 21 812 766

AROA BIOSURGERY LIMITED 2 Kingsford Smith Place, Airport Oaks Phone: +64 9 8693035 Auckland 2022, New Zealand US (844)-793-0490

PG | 1